 Kathryn Colborn
Concepts (425)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 10 | 2023 | 970 | 2.730 |
Why?
| | Postoperative Complications | 30 | 2025 | 2473 | 2.370 |
Why?
| | Quality Improvement | 14 | 2023 | 1095 | 1.300 |
Why?
| | Sepsis | 6 | 2023 | 572 | 1.290 |
Why?
| | Urinary Tract Infections | 3 | 2022 | 151 | 1.290 |
Why?
| | Surgical Procedures, Operative | 5 | 2023 | 244 | 1.250 |
Why?
| | Surgical Wound Infection | 7 | 2025 | 283 | 1.230 |
Why?
| | Pancreatic Neoplasms | 10 | 2024 | 881 | 1.220 |
Why?
| | Shock, Septic | 4 | 2023 | 209 | 1.180 |
Why?
| | Machine Learning | 7 | 2023 | 442 | 1.180 |
Why?
| | Malaria | 4 | 2023 | 59 | 1.090 |
Why?
| | Retrospective Studies | 46 | 2025 | 14455 | 0.830 |
Why?
| | Models, Statistical | 4 | 2020 | 623 | 0.800 |
Why?
| | Postoperative Hemorrhage | 2 | 2023 | 87 | 0.800 |
Why?
| | Databases, Factual | 15 | 2025 | 1266 | 0.780 |
Why?
| | Humans | 123 | 2025 | 129248 | 0.770 |
Why?
| | Malaria, Falciparum | 2 | 2018 | 26 | 0.770 |
Why?
| | Plasmodium vivax | 2 | 2018 | 3 | 0.690 |
Why?
| | Malaria, Vivax | 2 | 2018 | 4 | 0.690 |
Why?
| | Adenocarcinoma | 5 | 2024 | 898 | 0.670 |
Why?
| | Pain | 2 | 2023 | 786 | 0.670 |
Why?
| | Artificial Intelligence | 1 | 2023 | 246 | 0.660 |
Why?
| | Patient Reported Outcome Measures | 7 | 2024 | 372 | 0.660 |
Why?
| | Surgeons | 4 | 2025 | 260 | 0.630 |
Why?
| | Pneumonia | 3 | 2023 | 616 | 0.620 |
Why?
| | Risk Assessment | 17 | 2024 | 3233 | 0.620 |
Why?
| | Breast Neoplasms | 7 | 2024 | 2140 | 0.620 |
Why?
| | Palliative Care | 7 | 2024 | 706 | 0.610 |
Why?
| | Inpatients | 4 | 2023 | 462 | 0.600 |
Why?
| | Thoracic Surgery | 3 | 2025 | 122 | 0.580 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 29 | 0.570 |
Why?
| | Poisson Distribution | 1 | 2018 | 73 | 0.570 |
Why?
| | Neoadjuvant Therapy | 8 | 2024 | 381 | 0.570 |
Why?
| | Health Plan Implementation | 1 | 2019 | 137 | 0.570 |
Why?
| | Risk Factors | 25 | 2025 | 9745 | 0.540 |
Why?
| | Middle Aged | 39 | 2025 | 31087 | 0.530 |
Why?
| | Hospitalization | 6 | 2021 | 2052 | 0.530 |
Why?
| | Mosquito Control | 2 | 2023 | 27 | 0.530 |
Why?
| | Aged | 31 | 2025 | 22032 | 0.500 |
Why?
| | Female | 55 | 2025 | 68543 | 0.490 |
Why?
| | Mosquito Nets | 1 | 2015 | 2 | 0.490 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2023 | 270 | 0.490 |
Why?
| | Anopheles | 1 | 2015 | 14 | 0.480 |
Why?
| | Quality of Life | 10 | 2024 | 2685 | 0.470 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2023 | 282 | 0.470 |
Why?
| | Adult | 36 | 2025 | 35495 | 0.450 |
Why?
| | Drug Prescriptions | 3 | 2021 | 247 | 0.450 |
Why?
| | Male | 48 | 2025 | 63501 | 0.450 |
Why?
| | Thoracic Surgical Procedures | 2 | 2025 | 69 | 0.420 |
Why?
| | Mastectomy, Segmental | 2 | 2024 | 85 | 0.400 |
Why?
| | Patient Discharge | 2 | 2020 | 835 | 0.400 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2023 | 58 | 0.400 |
Why?
| | Hospital Mortality | 1 | 2016 | 846 | 0.390 |
Why?
| | Robotic Surgical Procedures | 2 | 2024 | 114 | 0.380 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 72 | 0.380 |
Why?
| | Preoperative Care | 3 | 2024 | 339 | 0.370 |
Why?
| | Algorithms | 4 | 2019 | 1613 | 0.370 |
Why?
| | Primary Health Care | 2 | 2019 | 1678 | 0.360 |
Why?
| | Mastectomy | 4 | 2024 | 131 | 0.360 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 483 | 0.340 |
Why?
| | Incidence | 8 | 2023 | 2636 | 0.340 |
Why?
| | Influenza, Human | 3 | 2021 | 601 | 0.340 |
Why?
| | Hospitals | 4 | 2025 | 630 | 0.330 |
Why?
| | Child, Preschool | 14 | 2023 | 10456 | 0.330 |
Why?
| | Emergency Treatment | 2 | 2021 | 111 | 0.320 |
Why?
| | Cohort Studies | 11 | 2024 | 5408 | 0.290 |
Why?
| | Aged, 80 and over | 10 | 2024 | 7055 | 0.290 |
Why?
| | Research Design | 3 | 2022 | 1043 | 0.290 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 240 | 0.280 |
Why?
| | Colorado | 8 | 2025 | 4406 | 0.280 |
Why?
| | Cardiac Surgical Procedures | 2 | 2023 | 499 | 0.280 |
Why?
| | Pancreatectomy | 3 | 2024 | 241 | 0.280 |
Why?
| | United States | 18 | 2024 | 13828 | 0.280 |
Why?
| | Logistic Models | 5 | 2023 | 1984 | 0.280 |
Why?
| | Patient Satisfaction | 4 | 2024 | 632 | 0.270 |
Why?
| | Prognosis | 10 | 2024 | 3772 | 0.270 |
Why?
| | Seasons | 3 | 2025 | 494 | 0.270 |
Why?
| | Chagas Disease | 2 | 2018 | 38 | 0.270 |
Why?
| | Autism Spectrum Disorder | 2 | 2023 | 386 | 0.270 |
Why?
| | Rectal Neoplasms | 2 | 2019 | 136 | 0.260 |
Why?
| | Mass Drug Administration | 3 | 2023 | 7 | 0.260 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2021 | 305 | 0.260 |
Why?
| | Asthma | 1 | 2019 | 2220 | 0.240 |
Why?
| | Elective Surgical Procedures | 2 | 2024 | 164 | 0.240 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2024 | 379 | 0.240 |
Why?
| | Treatment Outcome | 13 | 2025 | 10199 | 0.230 |
Why?
| | CA-19-9 Antigen | 1 | 2024 | 22 | 0.230 |
Why?
| | Heart Defects, Congenital | 2 | 2022 | 757 | 0.230 |
Why?
| | Heart Failure | 4 | 2018 | 2135 | 0.230 |
Why?
| | Emergency Service, Hospital | 3 | 2020 | 1896 | 0.230 |
Why?
| | Varicose Veins | 1 | 2024 | 17 | 0.220 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 909 | 0.210 |
Why?
| | Hypothermia | 1 | 2023 | 34 | 0.210 |
Why?
| | Specialties, Surgical | 2 | 2021 | 73 | 0.210 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 32 | 0.210 |
Why?
| | Metastasectomy | 1 | 2023 | 19 | 0.210 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 47 | 0.210 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 1946 | 0.210 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 32 | 0.200 |
Why?
| | Young Adult | 11 | 2020 | 12388 | 0.200 |
Why?
| | Multivariate Analysis | 2 | 2023 | 1497 | 0.200 |
Why?
| | Infant | 10 | 2025 | 8975 | 0.200 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1267 | 0.200 |
Why?
| | Insecticides | 1 | 2023 | 33 | 0.200 |
Why?
| | Europe | 1 | 2023 | 363 | 0.200 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 60 | 0.200 |
Why?
| | MEF2 Transcription Factors | 1 | 2022 | 60 | 0.200 |
Why?
| | Risk Adjustment | 1 | 2023 | 79 | 0.200 |
Why?
| | Microcephaly | 1 | 2023 | 87 | 0.200 |
Why?
| | Carotid Stenosis | 1 | 2023 | 84 | 0.200 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 42 | 0.200 |
Why?
| | Telemetry | 1 | 2022 | 39 | 0.200 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2023 | 72 | 0.200 |
Why?
| | Time-to-Treatment | 1 | 2024 | 179 | 0.200 |
Why?
| | Polypharmacy | 1 | 2023 | 84 | 0.190 |
Why?
| | Medication Therapy Management | 1 | 2023 | 72 | 0.190 |
Why?
| | Syncope | 1 | 2022 | 51 | 0.190 |
Why?
| | Information Dissemination | 1 | 2024 | 205 | 0.190 |
Why?
| | Drug Hypersensitivity | 1 | 2023 | 81 | 0.190 |
Why?
| | Pain, Postoperative | 2 | 2021 | 233 | 0.190 |
Why?
| | Pneumonectomy | 1 | 2023 | 151 | 0.190 |
Why?
| | Adolescent | 13 | 2023 | 20303 | 0.190 |
Why?
| | Galectins | 1 | 2022 | 22 | 0.190 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 41 | 0.190 |
Why?
| | Delirium | 1 | 2023 | 78 | 0.190 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 99 | 0.190 |
Why?
| | Ivermectin | 1 | 2021 | 13 | 0.180 |
Why?
| | Mozambique | 2 | 2018 | 7 | 0.180 |
Why?
| | Communication | 2 | 2025 | 836 | 0.180 |
Why?
| | Vascular Surgical Procedures | 1 | 2024 | 294 | 0.180 |
Why?
| | Knee Joint | 2 | 2021 | 372 | 0.180 |
Why?
| | Program Evaluation | 3 | 2021 | 872 | 0.180 |
Why?
| | Dysbiosis | 1 | 2022 | 169 | 0.180 |
Why?
| | Oxycodone | 1 | 2021 | 42 | 0.180 |
Why?
| | New Guinea | 2 | 2018 | 4 | 0.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1555 | 0.170 |
Why?
| | Surgery Department, Hospital | 1 | 2020 | 20 | 0.170 |
Why?
| | Gastric Bypass | 1 | 2022 | 107 | 0.170 |
Why?
| | Terminal Care | 1 | 2023 | 214 | 0.170 |
Why?
| | Arthroplasty | 1 | 2020 | 47 | 0.170 |
Why?
| | Intensive Care Units | 2 | 2022 | 736 | 0.170 |
Why?
| | Faculty | 1 | 2021 | 137 | 0.170 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 45 | 0.170 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2022 | 231 | 0.170 |
Why?
| | Hypersensitivity | 1 | 2023 | 248 | 0.170 |
Why?
| | Artemisinins | 1 | 2019 | 2 | 0.160 |
Why?
| | Zebrafish Proteins | 1 | 2022 | 266 | 0.160 |
Why?
| | Antimalarials | 1 | 2019 | 30 | 0.160 |
Why?
| | General Surgery | 1 | 2021 | 152 | 0.160 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2019 | 129 | 0.160 |
Why?
| | Waiting Lists | 2 | 2021 | 237 | 0.160 |
Why?
| | Latent Tuberculosis | 1 | 2010 | 67 | 0.160 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 247 | 0.160 |
Why?
| | Vaccination | 2 | 2025 | 1347 | 0.160 |
Why?
| | Rural Population | 2 | 2020 | 513 | 0.160 |
Why?
| | Prisons | 1 | 2010 | 79 | 0.160 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 284 | 0.150 |
Why?
| | Laparoscopy | 1 | 2023 | 449 | 0.150 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 70 | 0.150 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 175 | 0.150 |
Why?
| | Organ Transplantation | 1 | 2021 | 228 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1497 | 0.150 |
Why?
| | Triage | 1 | 2021 | 206 | 0.150 |
Why?
| | Aftercare | 1 | 2020 | 203 | 0.150 |
Why?
| | Outpatients | 1 | 2022 | 367 | 0.150 |
Why?
| | Defibrillators, Implantable | 1 | 2022 | 300 | 0.150 |
Why?
| | Condoms, Female | 1 | 2008 | 2 | 0.150 |
Why?
| | Cognition | 2 | 2023 | 1122 | 0.150 |
Why?
| | Datasets as Topic | 1 | 2019 | 109 | 0.150 |
Why?
| | Burns | 1 | 2022 | 286 | 0.150 |
Why?
| | Social Marketing | 1 | 2008 | 13 | 0.150 |
Why?
| | Obesity, Morbid | 1 | 2022 | 240 | 0.150 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 35 | 0.150 |
Why?
| | Developed Countries | 1 | 2018 | 34 | 0.150 |
Why?
| | Hospitals, University | 1 | 2018 | 179 | 0.150 |
Why?
| | Community Participation | 1 | 2019 | 124 | 0.150 |
Why?
| | Child | 11 | 2023 | 20773 | 0.150 |
Why?
| | Quinolines | 1 | 2019 | 156 | 0.150 |
Why?
| | Ventricular Function | 1 | 2018 | 61 | 0.150 |
Why?
| | Reproductive Medicine | 1 | 2008 | 14 | 0.150 |
Why?
| | Zebrafish | 1 | 2022 | 458 | 0.150 |
Why?
| | Autistic Disorder | 1 | 2020 | 189 | 0.150 |
Why?
| | Patient Admission | 1 | 2019 | 181 | 0.150 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 154 | 0.150 |
Why?
| | Computers, Handheld | 1 | 2018 | 23 | 0.140 |
Why?
| | ROC Curve | 1 | 2019 | 502 | 0.140 |
Why?
| | Climate | 1 | 2018 | 86 | 0.140 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 430 | 0.140 |
Why?
| | Population Groups | 1 | 2018 | 60 | 0.140 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 94 | 0.140 |
Why?
| | Geography | 1 | 2018 | 186 | 0.140 |
Why?
| | Sentinel Surveillance | 1 | 2017 | 41 | 0.140 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2023 | 107 | 0.140 |
Why?
| | Condoms | 1 | 2008 | 103 | 0.140 |
Why?
| | Immunoglobulin A | 1 | 2019 | 200 | 0.140 |
Why?
| | Safety-net Providers | 1 | 2019 | 109 | 0.140 |
Why?
| | Qualitative Research | 1 | 2024 | 1215 | 0.140 |
Why?
| | Recovery of Function | 1 | 2021 | 641 | 0.140 |
Why?
| | Patient Compliance | 1 | 2021 | 563 | 0.140 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 108 | 0.140 |
Why?
| | Occupational Health | 1 | 2010 | 192 | 0.140 |
Why?
| | Epidemics | 1 | 2018 | 81 | 0.140 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 338 | 0.140 |
Why?
| | Lymph Node Excision | 3 | 2023 | 164 | 0.140 |
Why?
| | Anxiety Disorders | 1 | 2010 | 350 | 0.130 |
Why?
| | Cell Phone | 1 | 2017 | 70 | 0.130 |
Why?
| | Gastroenteritis | 1 | 2017 | 67 | 0.130 |
Why?
| | Students, Medical | 1 | 2021 | 315 | 0.130 |
Why?
| | Occupational Exposure | 1 | 2010 | 299 | 0.130 |
Why?
| | Influenza Vaccines | 1 | 2021 | 532 | 0.130 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 69 | 0.130 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 476 | 0.130 |
Why?
| | Parents | 1 | 2025 | 1308 | 0.130 |
Why?
| | Patient Readmission | 2 | 2020 | 652 | 0.130 |
Why?
| | Alcoholism | 1 | 2023 | 765 | 0.130 |
Why?
| | Fever | 1 | 2017 | 298 | 0.130 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 98 | 0.130 |
Why?
| | Forecasting | 1 | 2018 | 359 | 0.130 |
Why?
| | Follow-Up Studies | 5 | 2024 | 4886 | 0.130 |
Why?
| | Nurse Practitioners | 1 | 2018 | 132 | 0.120 |
Why?
| | Morbidity | 3 | 2022 | 300 | 0.120 |
Why?
| | Mass Screening | 2 | 2020 | 1149 | 0.120 |
Why?
| | Melanoma | 1 | 2022 | 729 | 0.120 |
Why?
| | Models, Organizational | 1 | 2016 | 146 | 0.120 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 376 | 0.120 |
Why?
| | Humidity | 1 | 2015 | 49 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2022 | 824 | 0.120 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 810 | 0.120 |
Why?
| | Mobile Applications | 1 | 2017 | 160 | 0.120 |
Why?
| | Healthcare Disparities | 2 | 2018 | 575 | 0.120 |
Why?
| | Advance Care Planning | 1 | 2018 | 202 | 0.120 |
Why?
| | Antibodies, Viral | 1 | 2019 | 601 | 0.120 |
Why?
| | Stroke | 1 | 2023 | 1070 | 0.120 |
Why?
| | Cannabidiol | 1 | 2016 | 108 | 0.120 |
Why?
| | Diarrhea | 3 | 2023 | 180 | 0.120 |
Why?
| | Emergency Medical Services | 1 | 2021 | 521 | 0.110 |
Why?
| | Anticonvulsants | 1 | 2016 | 209 | 0.110 |
Why?
| | Time Factors | 5 | 2024 | 6543 | 0.110 |
Why?
| | Massage | 2 | 2010 | 43 | 0.110 |
Why?
| | Survival Rate | 3 | 2024 | 1869 | 0.110 |
Why?
| | Models, Biological | 1 | 2021 | 1722 | 0.110 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1837 | 0.110 |
Why?
| | Family Practice | 1 | 2018 | 455 | 0.110 |
Why?
| | Environmental Exposure | 1 | 2018 | 462 | 0.110 |
Why?
| | Parasitemia | 1 | 2013 | 11 | 0.110 |
Why?
| | Chronic Pain | 1 | 2018 | 252 | 0.110 |
Why?
| | Research | 1 | 2016 | 416 | 0.100 |
Why?
| | Indians, North American | 1 | 2009 | 600 | 0.100 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1021 | 0.100 |
Why?
| | Software | 1 | 2018 | 606 | 0.100 |
Why?
| | Prospective Studies | 5 | 2024 | 7121 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2716 | 0.100 |
Why?
| | Medicaid | 1 | 2017 | 431 | 0.100 |
Why?
| | Epilepsy | 1 | 2016 | 322 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1364 | 0.100 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 539 | 0.100 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 285 | 0.100 |
Why?
| | Axilla | 2 | 2023 | 45 | 0.100 |
Why?
| | Temperature | 1 | 2015 | 634 | 0.100 |
Why?
| | Emergencies | 2 | 2025 | 155 | 0.100 |
Why?
| | Diagnostic Tests, Routine | 2 | 2024 | 102 | 0.100 |
Why?
| | Feedback | 2 | 2023 | 162 | 0.090 |
Why?
| | Washington | 2 | 2025 | 148 | 0.090 |
Why?
| | Patients | 2 | 2023 | 167 | 0.090 |
Why?
| | Pain Management | 2 | 2010 | 324 | 0.090 |
Why?
| | Prevalence | 3 | 2023 | 2554 | 0.090 |
Why?
| | Age Factors | 4 | 2021 | 3140 | 0.090 |
Why?
| | Uganda | 2 | 2023 | 70 | 0.090 |
Why?
| | Internship and Residency | 1 | 2021 | 1047 | 0.090 |
Why?
| | Disease Progression | 1 | 2019 | 2630 | 0.090 |
Why?
| | Lymphatic Metastasis | 2 | 2023 | 320 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2737 | 0.090 |
Why?
| | Heart Transplantation | 1 | 2017 | 721 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2342 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2053 | 0.080 |
Why?
| | Laboratories | 2 | 2021 | 108 | 0.080 |
Why?
| | Postoperative Period | 2 | 2021 | 329 | 0.080 |
Why?
| | Anti-HIV Agents | 1 | 2016 | 754 | 0.080 |
Why?
| | Societies, Medical | 2 | 2024 | 744 | 0.080 |
Why?
| | Pandemics | 3 | 2023 | 1482 | 0.080 |
Why?
| | Guatemala | 2 | 2023 | 313 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2015 | 622 | 0.080 |
Why?
| | Lymph Nodes | 2 | 2023 | 470 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 892 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2023 | 5382 | 0.070 |
Why?
| | Guideline Adherence | 2 | 2024 | 526 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2023 | 1197 | 0.070 |
Why?
| | Comorbidity | 2 | 2022 | 1544 | 0.070 |
Why?
| | Echocardiography | 2 | 2022 | 629 | 0.070 |
Why?
| | Immunization Programs | 1 | 2009 | 214 | 0.070 |
Why?
| | Referral and Consultation | 2 | 2023 | 727 | 0.070 |
Why?
| | Urban Population | 2 | 2020 | 441 | 0.070 |
Why?
| | Length of Stay | 2 | 2023 | 1120 | 0.060 |
Why?
| | School Health Services | 1 | 2009 | 233 | 0.060 |
Why?
| | Insurance Coverage | 2 | 2017 | 218 | 0.060 |
Why?
| | Affect | 1 | 2008 | 286 | 0.060 |
Why?
| | Pilot Projects | 2 | 2023 | 1584 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5045 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2022 | 5736 | 0.060 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1209 | 0.060 |
Why?
| | Cytokines | 2 | 2023 | 2013 | 0.060 |
Why?
| | Acute Disease | 2 | 2017 | 978 | 0.060 |
Why?
| | Body Mass Index | 2 | 2023 | 2272 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2010 | 557 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2024 | 208 | 0.050 |
Why?
| | Motivational Interviewing | 1 | 2025 | 101 | 0.050 |
Why?
| | Community Health Workers | 1 | 2023 | 55 | 0.050 |
Why?
| | Herniorrhaphy | 1 | 2023 | 57 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 13 | 0.050 |
Why?
| | Growth Disorders | 1 | 2023 | 80 | 0.050 |
Why?
| | Health Facilities | 1 | 2023 | 79 | 0.050 |
Why?
| | Sternotomy | 1 | 2022 | 25 | 0.050 |
Why?
| | Death | 1 | 2023 | 117 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2022 | 20 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 33 | 0.050 |
Why?
| | Vomiting | 1 | 2023 | 128 | 0.050 |
Why?
| | Papua New Guinea | 1 | 2012 | 8 | 0.050 |
Why?
| | Burn Units | 1 | 2022 | 42 | 0.050 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 1702 | 0.050 |
Why?
| | Breast | 1 | 2023 | 153 | 0.050 |
Why?
| | Cough | 1 | 2023 | 116 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 45 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2721 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2023 | 196 | 0.050 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 105 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2023 | 645 | 0.050 |
Why?
| | Neurosurgical Procedures | 1 | 2023 | 166 | 0.050 |
Why?
| | Survival Analysis | 1 | 2024 | 1269 | 0.050 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 53 | 0.050 |
Why?
| | Demography | 1 | 2022 | 279 | 0.050 |
Why?
| | Gastrectomy | 1 | 2022 | 100 | 0.050 |
Why?
| | Sample Size | 1 | 2021 | 116 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 469 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2023 | 326 | 0.040 |
Why?
| | Preoperative Period | 1 | 2021 | 114 | 0.040 |
Why?
| | Habits | 1 | 2020 | 43 | 0.040 |
Why?
| | Research Personnel | 1 | 2022 | 155 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 621 | 0.040 |
Why?
| | Focus Groups | 1 | 2023 | 450 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 208 | 0.040 |
Why?
| | Lung | 2 | 2024 | 3926 | 0.040 |
Why?
| | Censuses | 1 | 2020 | 27 | 0.040 |
Why?
| | Reoperation | 1 | 2023 | 541 | 0.040 |
Why?
| | South Africa | 1 | 2021 | 192 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 132 | 0.040 |
Why?
| | Animals | 3 | 2022 | 35307 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1199 | 0.040 |
Why?
| | Policy | 1 | 2021 | 143 | 0.040 |
Why?
| | Fear | 1 | 2023 | 350 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 244 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 479 | 0.040 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 43 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 233 | 0.040 |
Why?
| | Mentors | 1 | 2021 | 178 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2023 | 1290 | 0.040 |
Why?
| | Urination Disorders | 1 | 2019 | 13 | 0.040 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 10 | 0.040 |
Why?
| | Organoplatinum Compounds | 1 | 2019 | 41 | 0.040 |
Why?
| | Risk | 1 | 2022 | 854 | 0.040 |
Why?
| | Leucovorin | 1 | 2019 | 69 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 355 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 514 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 505 | 0.040 |
Why?
| | Kenya | 1 | 2019 | 107 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 457 | 0.040 |
Why?
| | Cardiovascular Nursing | 1 | 2018 | 3 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 373 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 531 | 0.040 |
Why?
| | Drug Combinations | 1 | 2019 | 330 | 0.040 |
Why?
| | Colombia | 1 | 2018 | 36 | 0.040 |
Why?
| | Fluorouracil | 1 | 2019 | 198 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2010 | 263 | 0.040 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 366 | 0.040 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2019 | 146 | 0.040 |
Why?
| | Biomedical Research | 1 | 2024 | 637 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 2009 | 243 | 0.040 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1173 | 0.040 |
Why?
| | Chronic Disease | 1 | 2024 | 1715 | 0.040 |
Why?
| | Patient-Centered Care | 1 | 2023 | 505 | 0.040 |
Why?
| | Rectum | 1 | 2019 | 170 | 0.040 |
Why?
| | Coinfection | 1 | 2019 | 131 | 0.040 |
Why?
| | Mortality | 1 | 2019 | 307 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 958 | 0.030 |
Why?
| | Odds Ratio | 1 | 2010 | 1018 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 757 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2021 | 546 | 0.030 |
Why?
| | Viral Load | 1 | 2019 | 448 | 0.030 |
Why?
| | Proctitis | 1 | 2016 | 6 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 732 | 0.030 |
Why?
| | Mental Health | 1 | 2023 | 685 | 0.030 |
Why?
| | Urogenital System | 1 | 2016 | 16 | 0.030 |
Why?
| | Latin America | 1 | 2016 | 87 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 438 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 306 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2008 | 150 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 251 | 0.030 |
Why?
| | Prisoners | 1 | 2008 | 141 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2017 | 126 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 962 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 754 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2016 | 135 | 0.030 |
Why?
| | Self Care | 1 | 2018 | 365 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 484 | 0.030 |
Why?
| | Electrocardiography | 1 | 2018 | 608 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 910 | 0.030 |
Why?
| | Plant Extracts | 1 | 2016 | 198 | 0.030 |
Why?
| | Hemorrhage | 1 | 2019 | 678 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 265 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1647 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 819 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 851 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 785 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3074 | 0.030 |
Why?
| | Neoplasms | 1 | 2008 | 2449 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3079 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2020 | 3377 | 0.030 |
Why?
| | Sex Factors | 1 | 2018 | 1965 | 0.020 |
Why?
| | Health Promotion | 1 | 2008 | 719 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2737 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 3966 | 0.020 |
Why?
| | Registries | 1 | 2018 | 1895 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2879 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2008 | 271 | 0.020 |
Why?
| | Veterans | 1 | 2009 | 1374 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2009 | 899 | 0.010 |
Why?
|
|
Colborn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|